1. Home
  2. RLMD vs QTTB Comparison

RLMD vs QTTB Comparison

Compare RLMD & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • QTTB
  • Stock Information
  • Founded
  • RLMD 2004
  • QTTB 2015
  • Country
  • RLMD United States
  • QTTB United States
  • Employees
  • RLMD N/A
  • QTTB N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • QTTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • RLMD Health Care
  • QTTB Health Care
  • Exchange
  • RLMD Nasdaq
  • QTTB Nasdaq
  • Market Cap
  • RLMD 20.3M
  • QTTB 18.9M
  • IPO Year
  • RLMD N/A
  • QTTB N/A
  • Fundamental
  • Price
  • RLMD $0.59
  • QTTB $2.00
  • Analyst Decision
  • RLMD Buy
  • QTTB Hold
  • Analyst Count
  • RLMD 3
  • QTTB 8
  • Target Price
  • RLMD $5.00
  • QTTB $24.00
  • AVG Volume (30 Days)
  • RLMD 206.5K
  • QTTB 3.8M
  • Earning Date
  • RLMD 08-07-2025
  • QTTB 08-11-2025
  • Dividend Yield
  • RLMD N/A
  • QTTB N/A
  • EPS Growth
  • RLMD N/A
  • QTTB N/A
  • EPS
  • RLMD N/A
  • QTTB N/A
  • Revenue
  • RLMD N/A
  • QTTB N/A
  • Revenue This Year
  • RLMD N/A
  • QTTB N/A
  • Revenue Next Year
  • RLMD N/A
  • QTTB N/A
  • P/E Ratio
  • RLMD N/A
  • QTTB N/A
  • Revenue Growth
  • RLMD N/A
  • QTTB N/A
  • 52 Week Low
  • RLMD $0.24
  • QTTB $1.35
  • 52 Week High
  • RLMD $3.98
  • QTTB $53.79
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 44.70
  • QTTB 48.73
  • Support Level
  • RLMD $0.60
  • QTTB $2.02
  • Resistance Level
  • RLMD $0.67
  • QTTB $2.33
  • Average True Range (ATR)
  • RLMD 0.06
  • QTTB 0.29
  • MACD
  • RLMD -0.00
  • QTTB -0.04
  • Stochastic Oscillator
  • RLMD 16.42
  • QTTB 13.51

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Share on Social Networks: